Licorice Root & Whitening Botanicals: Glabridin Concentration & Tyrosinase Inhibition

Overview #

Glabridin is not the only tyrosinase inhibitor in the botanicals toolkit, but it is the one most brands get wrong. The concentration looks simple on a spec sheet — 40% extract, 0.5% in formula — and then the product turns yellow by week six and the brand wonders what happened. We’ve been formulating licorice-based brightening systems for over a decade, and the failure modes are consistent enough that we now treat ingredient selection as a structured decision, not a preference. This guide walks through the criteria we apply before we commit to a brightening botanical system for any new brief.

The Four Variables That Actually Determine Performance #

Most brand partners come to us focused on glabridin percentage. That’s one variable. The others matter just as much, and in some cases more.

1. Glabridin assay purity: the 40% trap

Licorice root extract is sold at wildly different standardization levels — 10%, 20%, 40%, even 98% isolate. The 40% grade is the most common in cosmetic supply chains, and it’s where we see the most inconsistency. We’ve tested five different 40% glabridin extracts from four suppliers over the past three years. Actual glabridin content by HPLC ranged from 34% to 47% across those batches. That’s a 38% swing in active load if you’re dosing by extract weight rather than confirmed assay. We now require a Certificate of Analysis with HPLC confirmation on every incoming batch, and we hold a ±5% tolerance on declared glabridin content before we release to production.

2. In-formula concentration: where the clinical data actually sits

The tyrosinase inhibition data for glabridin is reasonably solid at 0.5% glabridin in formula. Below 0.3%, we’re not confident the effect is meaningful in a leave-on product. One double-blind, vehicle-controlled RCT (n=40, 12 weeks, twice-daily application) showed a 29% reduction in melanin index versus baseline at 0.5% glabridin, compared to 11% for the vehicle control. What that study doesn’t capture — and what we’ve learned from our own batches — is that the delivery system matters enormously. The same 0.5% glabridin in a simple emulsion versus a liposomal carrier gave us visibly different outcomes in our in-house tyrosinase inhibition assay. The number on the label is not the whole story.

3. Oxidative stability: the yellow problem

Glabridin oxidizes. This is the single most common failure mode we see in brightening briefs. At pH above 6.0, in the presence of iron ions or UV exposure, glabridin degrades to yellow-brown oxidation products within four to eight weeks. We stabilize it at pH 5.0–5.5, use chelating agents (EDTA at 0.1% or phytic acid at 0.2–0.5%), and require opaque or UV-blocking packaging. Honestly, most brands underestimate this. They approve a beautiful white serum at T0 and then call us at T8 asking why it looks like turmeric.

4. Solubility and phase compatibility

Glabridin is lipophilic. It does not dissolve in water. This sounds obvious, but we still get briefs asking for a “water-based brightening toner with glabridin.” Short answer: don’t try to dissolve glabridin in the aqueous phase. It needs to go into an oil phase, a solubilizer system (propylene glycol, butylene glycol at 5–10%), or an encapsulated delivery format. When brands push for a clear water-based format, we usually redirect them toward licorice water (deglycyrrhizinated licorice extract, water-soluble fraction) or a combination system with tranexamic acid. Not the same mechanism, but more format-compatible.

Botanical Brightening Actives: Decision Matrix #

When a brief comes in, we map the key actives against the criteria that matter for production viability. This is the internal comparison we run before recommending a system.

A few things worth noting about this table. Kojic acid is under active EU Cosmetics Regulation 1223/2009 review — the current 1% leave-on limit has been flagged for potential tightening by the SCCS Scientific Opinion process. We’ve already had two brand partners quietly reformulate away from kojic acid in anticipation. Alpha-arbutin hydrolysis to hydroquinone is a real concern at pH below 4.0 — drop below that and you’re in regulatory grey territory in the EU. Most brands don’t realize this until we tell them.

For a deeper look at how we handle vitamin C alongside botanical actives, see our Vitamin C & Antioxidant Systems formulation guide.

Where Most Brands Get This Wrong #

The brief usually says: “We want a brightening serum with licorice root, vitamin C, and niacinamide — all in one product.” We hear this constantly. And the instinct makes sense from a marketing angle — stack the actives, tell a richer story on pack.

The problem is phase incompatibility and pH conflict. Glabridin wants pH 5.0–5.5 and an oil phase. Ascorbic acid wants pH 3.0–3.5 and an aqueous phase. Niacinamide is fine across a wide pH range but converts to nicotinic acid (niacin flush risk) in highly acidic conditions. You cannot optimize all three in a single-phase system without compromising at least one of them.

What we actually do in these cases: separate the actives into a two-product system, or use encapsulation to isolate the pH-sensitive components. Encapsulation sounds elegant until you price it — roughly 3× the raw material cost for the encapsulated fraction, and minimum order quantities for encapsulated glabridin typically start at 25 kg, which pushes total batch cost up significantly for indie brands at MOQ 1,000–2,000 units.

This is usually where projects go sideways. The brand wants the full stack, the cost comes back, and then we spend three weeks negotiating down to a simpler system that should have been the starting point.

One pilot batch failed specifically because we tried to accommodate a client’s request for 0.5% glabridin and 15% vitamin C in the same emulsion at pH 3.8. The glabridin precipitated at that pH, the emulsion was visually unstable by day three, and we had to restart the development cycle. We now flag this combination as incompatible in our intake form before we accept the brief.

Scale-Up Realities for Licorice-Based Systems #

Lab scale is forgiving. Production scale is not.

At 500g lab batches, we can control mixing temperature, shear rate, and addition sequence manually. At 200 kg production scale, the glabridin-containing oil phase needs to be added at a specific temperature window — we’ve found 65–70°C works for most emulsion systems — and if the aqueous phase is too hot when they combine, you get localized glabridin degradation at the interface. The product looks fine at T0. By week four of accelerated stability testing at 40°C/75% RH, you see the yellowing begin.

We’ve also seen preservative efficacy failures in licorice-based systems at scale. The phenolic compounds in licorice extract interact with certain preservative systems — specifically, we’ve observed reduced efficacy of phenoxyethanol/ethylhexylglycerin blends when licorice extract load exceeds 2% (as extract, not as glabridin). Gram-negative challenge results that passed at lab scale failed at week eight of preservation challenge testing on the production batch. We now run a full ISO Standards ISO 11930 preservation efficacy test on every new licorice-based formula before we sign off on the system, regardless of what the lab-scale data showed.

Worked fine at 500g. At 200 kg, the preservative system needed a complete redesign.

For brands developing brightening systems alongside barrier-focused actives, our Barrier Repair & Sensitive Skin formulation notes cover how we balance low-pH brightening systems with skin tolerance requirements.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? These are the first two questions we ask when a brightening brief lands on our desk.

If you’re targeting the EU market, we need to know upfront whether you’re planning any kojic acid inclusion — the regulatory trajectory there is uncertain enough that we’d steer you away from it for a new launch. If you’re targeting the US market under FDA Cosmetics Guidelines, the active list is more permissive, but the clean beauty positioning many US brands carry creates its own constraints — EDTA, for example, is technically effective as a chelator for glabridin stabilization, but some clean beauty standards flag it. We’ve had to switch to phytic acid or sodium gluconate as alternatives, which work but require re-optimization of the chelation level.

If you’re targeting China, the NMPA Cosmetic Regulation whitening claim pathway requires specific documentation — glabridin-based systems can support a moisturizing or antioxidant claim more easily than a direct whitening claim, and we’ll walk you through the claim strategy before we finalize the formula.

Budget matters too. A glabridin system with encapsulation and airless pump packaging adds $0.40–$0.80 per unit on packaging alone, before you factor in the encapsulated active cost. For most indie brands at MOQ 1,000 units, that’s a meaningful COGS impact. We’ll always present a tiered option — a cost-optimized system and a performance-optimized system — so you can make the trade-off consciously.

What to include in your brief:

1. Target market(s) and primary regulatory jurisdiction (EU / US / China / other)
2. Desired on-pack claims — “brightening,” “whitening,” “dark spot correction,” or none
3. Product format (serum, cream, toner, mask) and preferred texture profile
4. Packaging format — opaque vs. transparent, airless vs. standard pump
5. Target retail price point and approximate MOQ (this determines encapsulation viability)
6. Any ingredient exclusions — clean beauty standards, vegan certification, fragrance-free
7. Existing hero actives you want to retain (so we can check compatibility before we start)

Frequently Asked Questions #

Q: We want to put “glabridin 0.5%” on our ingredient highlight panel — is that actually what’s in the formula?

It depends on how your extract is standardized. If you’re using a 40% glabridin extract at 1.25% in formula, the math gives you 0.5% glabridin — but only if the assay holds. We always verify by HPLC on the finished batch before we confirm the on-pack claim. Don’t rely on the supplier’s CoA alone.

Q: Can we combine licorice root with niacinamide in the same serum?

Yes, and it’s actually one of our more stable combinations. Niacinamide is compatible at pH 5.0–5.5, which is where we run glabridin systems anyway. Keep niacinamide at 2–5% and you get complementary mechanisms — tyrosinase inhibition from glabridin, melanosome transfer inhibition from niacinamide — without phase or pH conflict.

Q: How long does stability testing take for a new brightening formula?

Our standard accelerated stability protocol runs 12 weeks at 40°C/75% RH, with real-time ambient testing running in parallel. For licorice-based systems specifically, we add a color stability assessment at weeks 4, 8, and 12 because yellowing can appear before other stability parameters flag a problem. Expect a minimum of 14–16 weeks from formula lock to stability sign-off.

Q: We’ve heard glabridin has sensitization concerns — should we be worried?

The sensitization data on glabridin is mixed, and we’re still not fully convinced the risk is zero at higher concentrations. At 0.5% in formula, the available safety data is generally acceptable, and the SCCS Scientific Opinion process hasn’t flagged it as a high-concern sensitizer at cosmetic use levels. We do recommend a repeat insult patch test (RIPT) for any new glabridin formula before launch, especially for sensitive skin positioning.

Q: What’s the minimum order quantity for a custom glabridin brightening serum?

Our standard MOQ for a custom brightening serum is 1,000 units. If you want encapsulated glabridin, the raw material MOQ from our encapsulation supplier is 25 kg, which typically means a minimum batch size of 500 kg finished product — that’s roughly 5,000–10,000 units depending on fill weight. Most indie brands at early stage are better served by a non-encapsulated system at MOQ 1,000 until they’ve validated the market.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.